Pérez-Gómez Eduardo, Del Castillo Gaelle, Juan Francisco Santibáñez, López-Novoa Jose Miguel, Bernabéu Carmelo, Quintanilla Miguel
Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid, Madrid, Spain.
ScientificWorldJournal. 2010 Dec 14;10:2367-84. doi: 10.1100/tsw.2010.230.
Endoglin (CD105) is an auxiliary membrane receptor of transforming growth factor beta (TGF-β) that interacts with type I and type II TGF-β receptors and modulates TGF-β signaling. Endoglin is overexpressed in the tumor-associated vascular endothelium, where it modulates angiogenesis. This feature makes endoglin a promising target for antiangiogenic cancer therapy. In addition, recent studies on human and experimental models of carcinogenesis point to an important tumor cell-autonomous role of endoglin by regulating proliferation, migration, invasion, and metastasis. These studies suggest that endoglin behaves as a suppressor of malignancy in experimental and human epithelial carcinogenesis, although it can also promote metastasis in other types of cancer. In this review, we evaluate the implication of endoglin in tumor development underlying studies developed in our laboratories in recent years.
内皮糖蛋白（CD105）是转化生长因子β（TGF-β）的辅助膜受体，它与I型和II型TGF-β受体相互作用并调节TGF-β信号传导。内皮糖蛋白在肿瘤相关血管内皮中过度表达，在那里它调节血管生成。这一特性使内皮糖蛋白成为抗血管生成癌症治疗的一个有前景的靶点。此外，最近关于人类致癌模型和实验模型的研究指出，内皮糖蛋白通过调节增殖、迁移、侵袭和转移在肿瘤细胞自主发挥重要作用。这些研究表明，在内皮细胞癌发生的实验模型和人类模型中，内皮糖蛋白表现为恶性肿瘤的抑制因子，尽管它也可以促进其他类型癌症的转移。在这篇综述中，我们评估了近年来我们实验室开展的研究中内皮糖蛋白在肿瘤发生中的意义。
